Shire receives FDA approval of Daytrana for ADHD in adolescents

Published on July 7, 2010 at 1:19 AM · No Comments

Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years.  Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years.  Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).

"The FDA approval of Daytrana for adolescents now extends this medication option to an additional group of ADHD patients who may benefit from ADHD treatment delivered by a patch," said Mike Yasick, senior vice president of the Shire ADHD business unit.  "This approval reinforces Shire's commitment to providing a varied and comprehensive portfolio of medicines to meet the diverse needs of ADHD patients."

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post